Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD

Autor: Mirjam de With, Leni van Doorn, Demi C. Maasland, Tessa A.M. Mulder, Esther Oomen-de Hoop, Bianca Mostert, Marjolein Y.V. Homs, Samira El Bouazzaoui, Ron H.J. Mathijssen, Ron H.N. van Schaik, Sander Bins

Publikováno v: Biomedicine & Pharmacotherapy, Vol 159, Iss , Pp 114232- (2023)

Aim of the study: Occurrence of hand-foot syndrome (HFS) during capecitabine treatment often results in treatment interruptions (26 %) or treatment discontinuation (17 %), and can severely decrease quality of life. In this study, we investigated whet

Externí odkaz: https://doaj.org/article/22d712ca5f2d4b6f9d5ea8fc0cd5da1f

Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer

Autor: Reno Debets, Edwin A. Basak, Daan P. Hurkmans, Sander Bins, Stijn L. W. Koolen, Astrid A. M. van der Veldt, Stefan Sleijfer, Ron H. J. Mathijssen, Joachim G. J. V. Aerts, Ron H. N. van Schaik, Cor H. van der Leest, Nina Schepers, Esther Oomen-De Hoop, Samira El Bouazzaoui

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)

Background A minority of patients with advanced non-small-cell lung cancer (NSCLC) benefit from treatment with immune checkpoint inhibitors (ICIs). Ineffective effector function of activated T and NK cells may lead to reduced tumor cell death, even w

Externí odkaz: https://doaj.org/article/81ec1929bfab4cc5a86e10e660b32778

DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events

Autor: Mirjam de With, Gemma Brufau, Laila A. van den Berg, Femke M. de Man, Marija Trajkovic, Martine F. Thijs, Rob Castel, Henricus J. Vermeer, Samira el Bouazzaoui, Amber van Hemel, Maja Matic, Ron H. J. Mathijssen, Sander Bins, Ron H. N. van Schaik

Publikováno v: JCO Precision Oncology, 6:e2200180. American Society of Clinical Oncology

PURPOSE Around 20%-30% of patients treated with fluoropyrimidines develop severe treatment-related adverse events (AEs). These are mainly caused by deficiency of dihydropyrimidine dehydrogenase, its main metabolizing enzyme. The DPYD*7 variant allele

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1286c626407c80471e1d705fd1074c5
https://doi.org/10.1200/po.22.00180

Influence of receptor polymorphisms on the response to alpha-adrenergic receptor blockers in pheochromocytoma patients

Autor: Annika M. A. Berends, Mathieu S. Bolhuis, Ilja M. Nolte, Edward Buitenwerf, Thera P. Links, Henri J. L. M. Timmers, Richard A. Feelders, Elisabeth M. W. Eekhoff, Eleonora P. M. Corssmit, Peter H. Bisschop, Harm R. Haak, Ron H. N. van Schaik, Samira el Bouazzaoui, Bob Wilffert, Michiel N. Kerstens

Publikováno v: Biomedicines, 10(4):896. MDPI AG
Berends, A M A, Bolhuis, M S, Nolte, I M, Buitenwerf, E, Links, T P, Timmers, H J L M, Feelders, R A, Eekhoff, E M W, Corssmit, E P M, Bisschop, P H, Haak, H R, van Schaik, R H N, el Bouazzaoui, S, Wilffert, B & Kerstens, M N 2022, ' Influence of Receptor Polymorphisms on the Response to α-Adrenergic Receptor Blockers in Pheochromocytoma Patients ', Biomedicines, vol. 10, no. 4, 896 . https://doi.org/10.3390/biomedicines10040896
Biomedicines, 10
Biomedicines, 10(4). MDPI
Biomedicines; Volume 10; Issue 4; Pages: 896
Biomedicines, 10, 4

Background: Presurgical treatment with an α-adrenergic receptor blocker is recommended to antagonize the catecholamine-induced α-adrenergic receptor mediated vasoconstriction in patients with pheochromocytoma or sympathetic paraganglioma (PPGL). Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b479b4a58befd91fc49c91713460170f
https://hdl.handle.net/1887/3563208

Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer

Autor: Samira El Bouazzaoui, Sander Bins, Astrid A M van der Veldt, Stefan Sleijfer, Ron H.N. van Schaik, Daan P. Hurkmans, Ron H.J. Mathijssen, Stijn L.W. Koolen, Joachim G.J.V. Aerts, Edwin A. Basak, Reno Debets, Cor van der Leest, Esther Oomen-de Hoop, Nina Schepers

Publikováno v: Journal for ImmunoTherapy of Cancer, 8(1):e000586. BioMed Central Ltd.
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)

BackgroundA minority of patients with advanced non-small-cell lung cancer (NSCLC) benefit from treatment with immune checkpoint inhibitors (ICIs). Ineffective effector function of activated T and NK cells may lead to reduced tumor cell death, even wh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61be15f4ecb85bda87440d856f59f3b7
https://pure.eur.nl/en/publications/cdcdba93-ba5f-4fb5-8d11-fcca4546f7ee